BELLUS Health (BLU – Research Report) received a Hold rating and a $5.00 price target from Bloom Burton analyst David Martin on July 6. The company’s shares closed last Wednesday at $2.96, close to its 52-week low of $2.52.
According to TipRanks.com, Martin is a 5-star analyst with an average return of 24.1% and a 46.9% success rate. Martin covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Knight Therapeutics, and ESSA Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BELLUS Health with a $9.73 average price target, representing a 209.9% upside. In a report issued on July 6, Mackie Research also downgraded the stock to Hold with a C$8.70 price target.
The company has a one-year high of $12.03 and a one-year low of $2.52. Currently, BELLUS Health has an average volume of 2.54M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.